

Eisai joins REMAP-CAP on innovative trial to combat COVID-19

06 July 2020 | News

Eisai's Eritoran Selected as the First Investigational Immune Modulation Therapy to Be Evaluated Across Multiple International Trial Sites



US based Global Coalition for Adaptive Research and Japanese firm Eisai Co., Ltd., in collaboration with UPMC (University of Pittsburgh Medical Center), have announced that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (AR andomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19.

Eritoran, an investigational TLR-4 antagonist discovered and developed by Eisai, has been selected as the first investigational immune modulation therapy to be evaluated in the moderate patient group of REMAP-COVID.

The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.

Previously observed to be safe in a large Phase 3 randomized trial in sepsis, *eritoran* is designed to suppress the over-production and release of various pro-inflammatory mediators ("cytokine storm") with the aim to protect against damage in COVID-19 patients' lungs and other organs.

REMAP-CAP is led by the world's leading critical care trialists and experts in pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP has enrolled over 1100 patients at 218 sites across North America, Europe, and Australia and New Zealand